Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China
Abstract Background Early neurological deterioration (END) is a critical determinant influencing the short-term prognosis of acute ischemic stroke (AIS) patients and is associated with increased mortality rates among hospitalized individuals. AIS frequently coexists with coronary heart disease (CHD)...
Saved in:
| Main Authors: | Xing Gong, Xinting Yu, Lanlan Pu, Yang Jiao, Lin Liu, Hua Cao, Xiaofei Ji |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Trials |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13063-024-08709-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01) -
PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01) -
Influencing factors of early neurological deterioration in COVID-19 -associated acute ischemic stroke
by: Jian Wang, et al.
Published: (2025-07-01) -
Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01) -
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
by: Xiaoxiao Zheng, et al.
Published: (2025-07-01)